The Role of Phenylalanine at Position 6 in Glucagon's Mechanism of Biological Action: Multiple Replacement Analogues of Glucagon
- 1 August 1997
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 40 (16) , 2555-2562
- https://doi.org/10.1021/jm960800d
Abstract
Extensive evidence gathered from structure-activity relationship analysis has identified and confirmed specific positions in the glucagon sequence that are important either for binding to its receptor or for signal transduction. Fifteen glucagon analogues have been designed and synthesized by incorporating structural changes in the N-terminal region of glucagon, in particular histidine-1, phenylalanine-6, and aspartic acid-9. This investigation was conducted to study the role of phenylalanine at position 6 on the glucagon mechanism of action. These glucagon analogues have been made by either deleting or substituting hydrophobic groups, hydrophilic groups, aromatic amino acids, or a d-phenylalanine residue at this position. The structures of the new analogues are as follows: [des-His 1,des-Phe6,Glu9]glucagon-NH2 (1); [des-His1,Ala6,Glu9]glucagon-NH2 (2); [des-His1,Tyr6,Glu9]glucagon-NH2 (3); [des-His1,Trp6,Glu9]glucagon-NH2 (4); [des-His1,d-Phe6,Glu9]glucagon-NH2 (5); [des-His1,Nle6,Glu9]glucagon-NH2 (6); [des-His1,Asp6,Glu9]glucagon-NH2 (7); [des-His1,des-Gly4,Glu9]glucagon-NH2 (8); [desPhe6,Glu9]glucagon-NH2(9); [des-Phe6]glucagon-NH2(10); [des-His1,des-Phe6]glucagon-NH2 (11); [des-His1,des-Phe6,Glu9]glucagon (12); [des-Phe6,Glu9]glucagon (13); [des-Phe6]glucagon (14); and [des-His1,des-Phe6]glucagon (15). The receptor binding potencies IC50 values are 48 (1), 126 (2), 40 (3), 19 (4), 100 (5), 48 (6), 2000 (7), 52 (8), 113 (9), 512 (10), 128 (11), 1000 (12), 2000 (13), 500 (14), and 200 nM (15). All analogues were found to be antagonists unable to activate the adenylate cyclase system even at concentrations as high as 10-5 M except for analogues 6 and 8, which were found to be weak partial agonists/partial antagonists with maximum stimulation between 6−12%. In competitive inhibition experiments, all the analogues caused a right shift of the glucagon-stimulated adenylate cyclase dose−response curve. The pA2 values were 8.20 (1), 6.40 (2), 6.20 (3), 6.25 (4), 6.30 (5), 6.30 (7), 6.05 (8), 6.20 (9), 6.30 (10), 6.25 (11), 6.10 (12), 6.20 (13), 6.20 (14), and 6.35 (15).Keywords
This publication has 33 references indexed in Scilit:
- [des His1, des Phe6, Glu9]glucagon amide: A newly designed “pure” glucagon antagonistBioorganic & Medicinal Chemistry Letters, 1995
- New glucagon analogues with conformational restrictions and altered amphiphilicity: Effects on binding, adenylate cyclase and glycogenolytic activitiesLife Sciences, 1993
- Expression cloning and signaling properties of the rat glucagon receptorScience, 1993
- Synthetic glucagon antagonists and partial agonistsInternational Journal of Peptide and Protein Research, 1991
- Semianalytical treatment of solvation for molecular mechanics and dynamicsJournal of the American Chemical Society, 1990
- Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanicsJournal of Computational Chemistry, 1990
- Solid phase peptide synthesis utilizing 9‐fluorenylmethoxycarbonyl amino acidsInternational Journal of Peptide and Protein Research, 1990
- Transient Raman evidence of the one-way cis to trans isomerization in the lowest excited triplet state of 2-styrylanthraceneJournal of the American Chemical Society, 1986
- Conformation of glucagon in a lipid-water interphase by 1H nuclear magnetic resonanceJournal of Molecular Biology, 1983
- Solid Phase Peptide Synthesis. I. The Synthesis of a TetrapeptideJournal of the American Chemical Society, 1963